JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

GALNT6, transcriptionally inhibited by KLF9, promotes osteosarcoma progression by increasing EFEMP1 expression via O-glycosylation modification

  • 0Department of Orthopedics, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Biochimica Et Biophysica Acta. Molecular Cell Research +

|

November 24, 2024

|

November 24, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

High expression of GALNT6 in osteosarcoma (OS) correlates with poor survival. Inhibiting GALNT6 reduces tumor growth, potentially through the KLF9/GALNT6/EFEMP1 pathway, offering new therapeutic strategies for this deadly cancer.

Area Of Science

  • Oncology
  • Molecular Biology
  • Biochemistry

Background

  • Osteosarcoma (OS) is a highly aggressive bone cancer with poor patient prognosis.
  • The role of N-acetylgalactosamine transferase 6 (GALNT6) in OS development and progression is currently unknown.
  • Understanding novel molecular pathways is crucial for developing effective OS treatments.

Purpose Of The Study

  • To investigate the functional role of GALNT6 in osteosarcoma.
  • To elucidate the molecular mechanism by which GALNT6 influences OS progression.
  • To identify potential therapeutic targets for osteosarcoma treatment.

Main Methods

  • Analysis of GALNT6 expression in OS tissues and correlation with patient survival.
  • In vitro and in vivo experiments using GALNT6-knockdown and overexpression lentiviral vectors.
  • Identification of interacting proteins and downstream targets using proteomics and co-immunoprecipitation/mass spectrometry.
  • Investigation of the KLF9/GALNT6/EFEMP1 regulatory axis.

Main Results

  • GALNT6 is significantly upregulated in OS tissues and associated with lower overall survival.
  • GALNT6 silencing inhibits OS cell proliferation and metastasis in vitro and in vivo.
  • KLF9 suppresses OS progression by inhibiting GALNT6 transcription, and GALNT6 overexpression can rescue KLF9's suppressive effects.
  • GALNT6 interacts with EFEMP1, increases its O-glycosylation, and reduces its degradation, thereby promoting OS progression.

Conclusions

  • GALNT6 plays a critical role in promoting osteosarcoma growth and metastasis.
  • The KLF9/GALNT6/EFEMP1 signaling pathway represents a potential therapeutic target for osteosarcoma.
  • Targeting GALNT6 or modulating EFEMP1 glycosylation may offer novel treatment strategies for OS.

Keywords: